ArticlePloS one2022

Pharmacological analysis of Empagliflozin: Acting through the CaMKII pathway in type 2 diabetes and acute cardiovascular events.

Guangyao ShaoPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.